Table 2.
Laboratory findings of COVID-19 patients with or without respiratory alkalosis.
| Respiratory alkalosis (n = 66) | No respiratory alkalosis (n = 164) | P-value | |
|---|---|---|---|
| White blood cell count, × 109/L, median (range) | 4.2 (0.8–10.4) | 4.6 (1.5–13.4) | 0.164 |
| Lymphocyte count, × 109/L, median (range) | 0.9 (0.1–3.7) | 1.2 (0.2–3.2) | 0.001 |
| Lymphocyte %, median (range) | 24.0 (5.5–46.6) | 27.5 (2.1–61.1) | 0.015 |
| Alanine aminotransferase, U/L, median (range) | 22.4 (8.1–93.7) | 18.8 (2.6–87.7) | 0.007 |
| Aspartate aminotransferase, U/L, median (range) | 27.7 (15.1–82.1) | 23.2 (2.0–78.8) | 0.000 |
| Total bilirubin, μmol/L, median (range) | 10.4 (5.1–162.1) | 11.0 (4.0–38.2) | 0.873 |
| C-reactive protein, mg/L, median (range) | 24.0 (0.2–101.9) | 12.0 (0.1–101.9) | 0.000 |
| Erythrocyte sedimentation rate, mm/h, median (range) | 53.0 (3.0–143.0) | 37.0 (1.0–114.0) | 0.012 |
| Procalcitonin, ≥0.05 ng/ml, No. (%) | 24 (36.4) | 39 (23.8) | 0.053 |
| Creatinine, μmol/L, median (range) | 46.8 (20.6–110.3) | 53.4 (21.9–255.7) | 0.058 |
| Creatine kinase, U/L, median (range) | 68.4 (11.3–986.4) | 76.1 (17.4–599.6) | 0.882 |
| Creatine kinase-MB, U/L, median (range) | 10.1 (1.0–221.7) | 9.5 (0.3–82.8) | 0.758 |
P < 0.05 was considered statistically significant (marked in bold).
COVID-19, coronavirus disease 2019.